What is the 13F Pro Quality Score for PLX?

13F Pro ranks Protalix BioTherapeutics, Inc. (PLX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PLX's current score at https://13fpro.ai/company/PLX (free sign-up required for the full ranking).

Which hedge funds own the most PLX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of PLX include BlackRock,, RENAISSANCE TECHNOLOGIES, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/company/PLX as soon as new 13F filings post.

Where does 13F Pro source PLX data?

All Protalix BioTherapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Protalix BioTherapeutics, Inc. files with the SEC under CIK 1006281. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PLX in?

Protalix BioTherapeutics, Inc. (PLX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

What drives PLX's revenue?

Per Protalix BioTherapeutics, Inc.'s latest 10-Q filed with the SEC on 2026-08-12, the biggest revenue drivers are: Revenues from selling goods ($19.8M, +28% YoY); Chiesi (Fabry disease) ($14.0M, +$4,242K YoY); Pfizer (Gaucher disease) ($4.3M, -$1,368K YoY). Figures are extracted from the filing text and machine-verified against the document. Full breakdown at https://13fpro.ai/company/PLX.

What are PLX's largest expenses?

Protalix BioTherapeutics, Inc.'s latest 10-Q reports these as the largest expense items: Cost of revenues ($7.8M, +32% YoY); Research and development expenses, net ($4.4M, -27% YoY); Selling, general, and administrative expenses ($3.1M, +19% YoY). Sourced directly from SEC EDGAR filing text for Q2 FY2026 (quarter ended June 30, 2026).

How often is PLX research updated on 13F Pro?

PLX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Protalix BioTherapeutics, Inc.(PLX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →NYSEsmall

Institutional-grade research for retail investors

SEC EDGAR: CIK 1006281 PLX stock profile & AI dashboard →

13F Pro Quality Score

58.0/100

Rank #1,056 of 2,961 stocksTOP 50%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.

Revenue Growth

68.0/100

Profitability

87.3/100

Balance Sheet

96.1/100

Earnings Quality

55.7/100

Free Cash Flow

54.5/100

Institutional Flow

11.8/100

Revenue Scale

12.9/100

Dilution Risk

26.7/100

Email me the moment this company reports earnings

AI Research Report

Two-page plain-English analysis: business, thesis, and three scenarios for the next two years. Refreshed every quarter.

Upgrade to Pro

Pro: 5 reports/month · Pro+: unlimitedOpinion, not investment advice. Do your own research.

Why PLX Scores 58/100

exact factor attribution · 2026-09-11

PLX's composite is driven by profitability and capital efficiency, held back by scale and institutional flow. Bars show each factor's exact push vs. a median company, using the same weights the ranking engine applies.

Profitability

+5.6 pts

87th pct

Capital efficiency

+4.6 pts

96th pct

Revenue growth

+3.6 pts

68th pct

Earnings growth

+1.6 pts

82th pct

Free cash flow

+0.7 pts

55th pct

Earnings quality

+0.6 pts

56th pct

Shareholder dilution

-1.2 pts

27th pct

Institutional flow

-1.9 pts

12th pct

Scale

-5.6 pts

13th pct

Latest change (2026-08-16): 56 → 38 · ↓ Profit margin 88→41; ↓ Free cash flow 54→13; despite ↑ Revenue growth 71→94

Factor percentiles are cross-sectional ranks across the ~2,800-stock scored universe, computed from SEC EDGAR filings. Not investment advice.

Unusual Activity in PLX

Events flagged as statistical outliers against PLX's own multi-year baseline — not fixed dollar thresholds.

Score shock2026-08-16
PLX quality score dropped 18 points (56→38) on a new filing
View source filing →

PLX Stock Analysis & AI Quality Score

Data updated 2026-09-11

AI stock analysis and institutional research for Protalix BioTherapeutics, Inc. (PLX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores PLX at 58.0/100 on a 32-signal composite quality model, placing it at rank #1,056 of 2,961 stocks — the top half of the AI-ranked universe. PLX scores in the top quartile across balance sheet strength (96.1), profitability (87.3). Areas of concern include institutional flow (11.8) and revenue scale (12.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 26.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Protalix BioTherapeutics, Inc. reports quarterly revenue of $19.9M, net income of $3.8M, an operating margin of 23.5%. Top institutional holders of PLX by reported 13-F value include BlackRock, RENAISSANCE TECHNOLOGIES, STATE STREET, based on the most recent SEC filings. PLX trades on the NYSE exchange and files with the SEC under CIK 1006281. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PLX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Protalix BioTherapeutics, Inc. directly from SEC EDGAR. Protalix BioTherapeutics, Inc.'s 13F Pro composite quality score has ranged between 12 and 65 since 2021, currently 58.0 — an improving long-term trajectory across 68 quarterly and live scoring snapshots.

✦

Fun facts about Protalix BioTherapeutics, Inc.

Quirks, history, and lore behind PLX — the kind of stuff that makes a stock memorable.

1
The Basics
A biopharmaceutical company · micro-cap · listed on NYSE American · headquartered in Israel with a U.S. presence.
2
The Numbers
Annual revenues in the tens of millions of dollars — modest by pharma standards — driven almost entirely by a single approved enzyme replacement therapy.
3
The History
Founded in the early 2000s, it pioneered a platform for growing therapeutic proteins inside plant cells rather than in traditional mammalian cell cultures.
4
The Secret
Its secret weapon is a carrot cell bioreactor system — yes, carrots — used to manufacture drugs for rare lysosomal storage disorders.
5
The Lore
It won FDA approval for taliglucerase alfa, the first plant-cell-derived therapeutic protein ever approved, offering an alternative for patients with Gaucher disease.
6
The Giveaway
An Israeli biotech that grows Gaucher disease medicine in carrot cells, trades under the ticker PLX, and proved that plants could be a serious drug factory.

▶ Think you know your stocks? Play the Daily Ticker

What's Driving PLX's Business? Latest 10-Q Breakdown

✓ 21/21 datapoints verified

AI-extracted from Protalix BioTherapeutics, Inc.'s 10-Q filed 2026-08-12 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Protalix's Q2 FY2026 revenue was $19.9M, up from $15.7M a year earlier, as a 28% increase in product sales — led by Chiesi — helped lift net income to $3.8M from $0.2M.

Biggest Revenue Drivers

Revenues from selling goods$19.8M+28% YoY

Increase resulted primarily from an increase in sales to Chiesi

Revenues from license and R&D services$68K-$150K YoY

Decrease resulted from a decrease in the amount of services provided to Chiesi

Biggest Revenue Drivers

Total revenue: $19.9M

Revenues from selling goods$19.8M+28% YoY

Increase resulted primarily from an increase in sales to Chiesi

Within Revenues from selling goods

Chiesi (Fabry disease)$14.0M+$4,242K YoY

Increase in sales to Chiesi

Pfizer (Gaucher disease)$4.3M-$1,368K YoY

Decrease resulted primarily from Pfizer's purchases to address unexpected manufacturing issues at Pfizer in 2025

Fiocruz (Brazil)$1.5M+$1,514K YoY

Increase resulted primarily from the timing of deliveries

Revenues from license and R&D services$68K-$150K YoY

Decrease resulted from a decrease in the amount of services provided to Chiesi

Largest Expense Items

Cost of revenues$7.8M+32% YoY

Increase resulted primarily from an increase in sales to Chiesi and to Fiocruz, partially offset by a decrease in sales to Pfizer

Research and development expenses, net$4.4M-27% YoY

Decrease resulted primarily from a $2.1 million grant recorded under the new Israeli R&D law as a reduction of R&D expenses

Selling, general, and administrative expenses$3.1M+19% YoY

Increase resulted primarily from higher salary and related expenses and selling expenses

Margins: Operating income rose to $4.7M from $1.2M a year earlier as 28% growth in product sales and a $2.1M Israeli R&D grant offset a 32% increase in cost of revenues tied to higher Chiesi and Fiocruz shipments.

Watch Items from the Filing

Chiesi, Pfizer, and Fiocruz are Protalix's only three commercial customers, contributing $14.0M, $4.3M, and $1.5M respectively of the $19.8M in product sales this quarter.
Fiocruz has not satisfied certain purchase commitments under the Brazil Agreement, which could have a material adverse effect and may lead to termination of the agreement.
New Section 232 tariffs on pharmaceutical products and APIs, announced April 2, 2026 and generally effective September 2026, could adversely affect the company's ability to commercialize products in the U.S.
Pfizer's Q2 2025 purchases to address unexpected manufacturing issues inflated the prior-year comparison, contributing to a $1,368K YoY decline in Pfizer sales; order timing does not reflect patient demand.
Net income was $3.8M in Q2 2026 versus $0.2M in Q2 2025, aided by a $2.1M Israeli R&D grant recognized as a reduction to R&D expense.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →Share on X

Revenue

Q2 2026

$19.9M

Net Income

Q2 2026

$3.8M

Free Cash Flow

Q2 2026

$-11.0M

Operating Margin

Q2 2026

23.5%

ROIC

Q2 2026

26.2%

Period

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro

Revenue

-1.2% YoY

$52.7MFY 2025

FY22 $47.6MFY23 $65.5MFY24 $53.4MFY25 $52.7M

Net Income

-325.2% YoY

$-6.6MFY 2025

FY22 $-14.9MFY23 $8.3MFY24 $2.9MFY25 $-6.6M

Operating Income

-240.4% YoY

$-5.5MFY 2025

FY22 $-13.0MFY23 $10.5MFY24 $3.9MFY25 $-5.5M

EPS (Diluted)

-300.0% YoY

$-0.08FY 2025

FY22 $-0.31FY23 $0.09FY24 $0.04FY25 $-0.08

Total Assets

+12.2% YoY

$82.3MFY 2025

FY22 $55.8MFY23 $84.4MFY24 $73.4MFY25 $82.3M

Op. Cash Flow

-238.3% YoY

$-12.0MFY 2025

FY22 $-25.0MFY23 $-1.3MFY24 $8.7MFY25 $-12.0M

Free Cash Flow

-284.4% YoY

$-13.6MFY 2025

FY22 $-25.6MFY23 $-2.5MFY24 $7.4MFY25 $-13.6M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$52.7M -1.2%	$53.4M -18.5%	$65.5M +37.5%	$47.6M +24.2%	$38.4M -39.0%	$62.9M
Net Income	$-6.6M -325.2%	$2.9M -64.7%	$8.3M +155.7%	$-14.9M +45.9%	$-27.6M -322.8%	$-6.5M
Operating Income	$-5.5M -240.4%	$3.9M -62.6%	$10.5M +180.4%	$-13.0M +36.4%	$-20.5M -855.1%	$2.7M
EPS (Diluted)	$-0.08 -300.0%	$0.04 -55.6%	$0.09 +129.0%	$-0.31 +50.0%	$-0.62 -181.8%	$-0.22
Total Assets	$82.3M +12.2%	$73.4M -13.0%	$84.4M +51.4%	$55.8M -24.3%	$73.7M +8.4%	$67.9M
Operating Cash Flow	$-12.0M -238.3%	$8.7M +758.1%	$-1.3M +94.7%	$-25.0M -143.1%	$-10.3M +60.6%	$-26.1M
Free Cash Flow	$-13.6M -284.4%	$7.4M +399.6%	$-2.5M +90.4%	$-25.6M -118.2%	$-11.7M +56.1%	$-26.8M

Get alerted when PLX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Protalix BioTherapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PLX

BlackRock, Inc.
$9.4M4,046,650 sh
RENAISSANCE TECHNOLOGIES LLC
$2.6M1,096,000 sh
STATE STREET CORP
$2.3M983,582 sh
GEODE CAPITAL MANAGEMENT, LLC
$2.3M979,995 sh
NORTHERN TRUST CORP
$2.1M922,340 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$1.2M510,639 sh
Stratos Wealth Partners, LTD.
$1.2M500,000 sh
DIMENSIONAL FUND ADVISORS LP
$1.1M493,424 sh
GOLDMAN SACHS GROUP INC
$1.1M475,922 sh
MARSHALL WACE, LLP
$1.1M452,757 sh

Fund	Value	Shares
BlackRock, Inc.	$9.4M	4,046,650
RENAISSANCE TECHNOLOGIES LLC	$2.6M	1,096,000
STATE STREET CORP	$2.3M	983,582
GEODE CAPITAL MANAGEMENT, LLC	$2.3M	979,995
NORTHERN TRUST CORP	$2.1M	922,340
VANGUARD PORTFOLIO MANAGEMENT LLC	$1.2M	510,639
Stratos Wealth Partners, LTD.	$1.2M	500,000
DIMENSIONAL FUND ADVISORS LP	$1.1M	493,424
GOLDMAN SACHS GROUP INC	$1.1M	475,922
MARSHALL WACE, LLP	$1.1M	452,757

Companies Similar to PLX

Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.

ELMD

Electromed, Inc.

AI score

Similar quality profile · 2 shared holders

Hillsdale Investment Management Inc.BAILARD, INC.

PDEX

PRO DEX INC

AI score

Similar quality profile · 1 shared holders

BAILARD, INC.

TMDX

TransMedics Group, Inc.

AI score

Similar quality profile · 1 shared holders

Phoenix Financial Ltd.

KMDA

KAMADA LTD

AI score

Similar quality profile · 3 shared holders

Phoenix Financial Ltd.Altshuler Shaham Ltd Y.D. More Investments Ltd

CRON

Cronos Group Inc.

AI score

Similar quality profile · 1 shared holders

Main Street Financial Solutions, LLC

NAGE

Niagen Bioscience, Inc.

AI score

Similar quality profile

LMAT

LEMAITRE VASCULAR INC

AI score

Similar quality profile

VCYT

VERACYTE, INC.

AI score

Similar quality profile · 1 shared holders

BAILARD, INC.

Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PLX on your watchlist

Track score changes the day Protalix BioTherapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PLX a good stock to buy?

13F Pro's AI-powered analysis of Protalix BioTherapeutics, Inc. (PLX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on NYSE). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PLX are available on the PLX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. PLX is classified as a small company.

Which hedge funds own PLX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PLX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Protalix BioTherapeutics, Inc.'s investment landscape.